AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that its cutting-edge antibody-drug conjugate (ADC) telisotuzumab vedotin has been granted breakthrough therapy designation (BTD) in China. This designation is for the treatment of advanced or metastatic epidermal growth factor receptor (EGFR) wild-type (WT) non-squamous (NSq) non-small cell lung cancer (NSCLC) that highly expresses c-Met protein (OE) and has progressed during or after platinum-based drug therapy.

Telisotuzumab vedotin is designed to target tumors with overexpression of c-Met, a receptor tyrosine kinase implicated in numerous solid tumors, including NSCLC. Following promising results from a Phase II study, the drug is now poised for evaluation in the Phase III TeliMET NSCLC-01 study. This trial will assess the efficacy and safety of telisotuzumab vedotin as a monotherapy in patients with pre-treated c-Met overexpressing NSCLC.- Flcube.com

Fineline Info & Tech